Baillie Gifford & Co. cut its stake in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 5.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,299,503 shares of the company's stock after selling 356,739 shares during the quarter. Baillie Gifford & Co. owned 3.39% of Doximity worth $176,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. Weiss Multi Strategy Advisers LLC grew its position in Doximity by 6.9% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 4,810 shares of the company's stock valued at $251,000 after acquiring an additional 310 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Doximity by 0.7% during the third quarter. Royal Bank of Canada now owns 66,135 shares of the company's stock valued at $1,404,000 after buying an additional 455 shares during the last quarter. Creative Financial Designs Inc. ADV increased its holdings in shares of Doximity by 16.7% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 3,301 shares of the company's stock worth $93,000 after buying an additional 473 shares during the period. EFG Asset Management Americas Corp. grew its position in Doximity by 7.3% during the 2nd quarter. EFG Asset Management Americas Corp. now owns 7,125 shares of the company's stock worth $242,000 after acquiring an additional 484 shares during the last quarter. Finally, Xponance Inc. grew its holdings in shares of Doximity by 2.7% in the third quarter. Xponance Inc. now owns 19,522 shares of the company's stock worth $414,000 after purchasing an additional 508 shares during the last quarter. Institutional investors own 87.19% of the company's stock.
Insider Buying and Selling
In other news, Director Kira Scherer Wampler sold 2,500 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $26.97, for a total value of $67,425.00. Following the sale, the director now directly owns 10,258 shares of the company's stock, valued at $276,658.26. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 39.40% of the stock is currently owned by company insiders.
Doximity Stock Down 2.2 %
Shares of DOCS stock traded down $0.57 during mid-day trading on Wednesday, reaching $25.85. 939,137 shares of the company's stock traded hands, compared to its average volume of 1,778,677. The company's 50-day moving average price is $27.88 and its 200-day moving average price is $25.91. The company has a market cap of $4.82 billion, a P/E ratio of 40.00, a P/E/G ratio of 3.24 and a beta of 1.17. Doximity, Inc. has a 12 month low of $19.71 and a 12 month high of $37.10.
Doximity (NASDAQ:DOCS - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.19 by $0.06. The business had revenue of $135.28 million for the quarter, compared to analyst estimates of $127.46 million. Doximity had a net margin of 29.39% and a return on equity of 16.08%. Equities analysts predict that Doximity, Inc. will post 0.72 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages have weighed in on DOCS. SVB Leerink assumed coverage on shares of Doximity in a research report on Monday, February 26th. They set a "market perform" rating and a $32.00 price target for the company. Barclays initiated coverage on Doximity in a research note on Wednesday, January 3rd. They issued an "equal weight" rating and a $31.00 target price on the stock. Truist Financial upped their price target on Doximity from $28.00 to $29.00 and gave the company a "hold" rating in a research report on Friday, February 9th. Bank of America lifted their price objective on Doximity from $29.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 23rd. Finally, Evercore ISI restated an "in-line" rating and set a $30.00 target price on shares of Doximity in a report on Tuesday, April 2nd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $28.82.
Read Our Latest Stock Analysis on DOCS
About Doximity
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Articles
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
